Summit Therapeutics Inc. (SMMT) AI Stock Analysis

Summit Therapeutics Inc., founded in 2003 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in discovering, developing, and commercializing medicines for infectious diseases. The company conducts clinical efforts primarily in the United States and Latin America, focusing on Clostridioides difficile infection (CDI). Its lead product candidate is ridinilazole, an oral antibiotic in Phase III clinical trials for treating CDI. Additionally, Summit is developing SMT-738 to combat multi-drug resistant pathogens such as carbapenem-resistant Enterobacteriaceae, along with the DDS-04 series targeting the Enterobacteriaceae family.

Summit's revenue has varied significantly based on historical licensing or collaborative income, falling from $57.1M in FY2018 and $43.0M in FY2019 to $628,875 in FY2020. Revenue stood at $1.8M in FY2021 before declining 67.8% to $583,190 in FY2022, resulting in a 5-year revenue CAGR of -47.2% from FY2017 to FY2022. Net losses widened from -$38.5M in FY2020 to -$86.1M in FY2021 and -$65.2M in FY2022. For the trailing twelve months, revenue was $0, with quarterly revenue growth falling 100.0% year-over-year in the latest quarter ended June 30, 2026.

As of June 30, 2026, Summit Therapeutics reported $690.7M in cash and short-term investments against $20.4M in total debt, yielding net cash of $670.3M. The company maintains a current ratio of 6.96 and a debt-to-equity ratio of 0.03 on $630.0M of shareholders' equity. Capital expenditures were $487,599 in FY2025. Financing activities have contributed to a 5-year share count change of 704.1%, while operating cash flow remained negative through FY2022 at -$33.9M.

With a market capitalization of $11.67B and an enterprise value of $12.44B, Summit Therapeutics trades at a forward P/E of 3.7x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-book ratio is 20.8x. Over the past year, the stock fell 33.4%, trailing the S&P 500 (SPY) gain of 16.8%. However, its 5-year return of 184.1% outperformed the S&P 500 return of 83.0% over the same timeframe.

Wall Street coverage includes 10 Strong Buy, 1 Buy, and 6 Hold ratings. The mean price target of $30.20 implies an upside of 106.4% from the last close of $14.63 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.84 on revenue of $2.9M. For the next fiscal year, 10 analysts estimate revenue of $42.0M and an EPS of -$0.88. The company has recorded 0 EPS beats over the last 4 quarters, with its next earnings date scheduled for October 19, 2026.

This page is an AI-written research summary of Summit Therapeutics Inc. (SMMT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SMMT income statement, SMMT balance sheet, SMMT key metrics, SMMT analyst forecast, SMMT chart. See the SMMT stock overview for the latest quote and news.